Emanuela Gentile

Emanuela Gentile

Auto-generated profile, based on publicly available information

Emanuela Gentile

Department of Genitourinary Medical Oncology, David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, Texas. 1

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney neoplasm; bone metastasis (BM) develops in 35% to 40% of metastatic patients and results in substantial morbidity and mortality, as well as medical costs. A key feature of ccRCC is the loss of function of the von Hippel–Lindau protein, which enhances angiogenesis via vascular endothelial growth factor release. Consequently, antiangiogenic tyrosine kinase inhibitors (TKI) emerged as a treatment for ccRCC. However, limited data about their efficacy in BM is available, and no systematic comparisons have been performed. We developed mouse models of bone and lung ccRCC tumors and compared their anticancer efficacy, impact on mouse survival, and mechanisms of action, including effects on tumor cells and both immune and nonimmune (blood vessels and osteoclasts) bone stromal components. This approach elucidates the efficacy of TKIs in ccRCC bone tumors to support rational interrogation and development of therapies. Significance: TKIs showed different efficacy in synchronous bone and lung metastases and did not eradicate tumors as single agents but induced extensive reprogramming of the BM microenvironment. This resulted in a significant decrease in neoangiogenic blood vessels, bone remodeling, and immune cell infiltration (including CD8 T cells) with altered spatial distribution.

13 December 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
EGEmanuela Gentile
Emanuela Gentile
AHAndrew Hahn
Andrew Hahn
JSJian Hua Song
Jian Hua Song
AHAnh Hoang
Anh Hoang
PSPeter Douglas Andrew Shepherd
Peter Douglas Andrew Shepherd
Theocharis PanaretakisTheocharis Panaretakis
Theocharis Panaretakis
Disease progression following androgen ablation was shown to be associated with upregulation of the glucocorticoid receptor (GR). Longitudinal monitoring of GR expression in circulating extracellular vesicles (EV) may reflect changes in the tumor cell and facilitates detection of acquired resistance. We utilized LNCaP, LREX cells and a patient-derived xenograft, MDA PDX 322-2-6a, for in vitro and in vivo experiments. Plasma-derived EVs were isolated from patients with localized high-risk prostate cancer undergoing androgen ablation. The mRNA levels of GR in EVs and their responsive genes were detected by transcriptome analysis, qRT-PCR and the protein levels by Western blot analysis. We detected changes in GR expression at mRNA and protein levels in EVs derived from LNCaP and LREX cells in in vitro studies. In in vivo experiments, LNCaP and the PDX MDA 322-2-6a–bearing mice were treated with enzalutamide. GR levels in plasma-derived EVs were increased only in those tumors that did not respond to enzalutamide. Treatment of mice bearing enzalutamide-resistant tumors with a GR inhibitor in combination with enzalutamide led to a transient pause in tumor growth in a subset of tumors and decreased GR levels intracellular and in plasma-derived EVs. In a subgroup of patients with high-risk localized prostate cancer treated with androgen signaling inhibition, GR was found upregulated in matching tissue and plasma EVs. These analyses showed that GR levels in plasma-derived EVs may be used for monitoring the transition of GR expression allowing for early detection of resistance to androgen ablation treatment. Significance: Longitudinal monitoring of GR expression in plasma-derived EVs from patients with prostate cancer treated with androgen signaling inhibitors facilitates early detection of acquisition of resistance to androgen receptor signaling inhibition in individual patients.

3 April 2025
Verified
Other
Open access
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
TKIs as a second-line treatment. A, Schematic representation of experimental design. B, D, and F, Representative images of bioluminescence signal in tibiae/lungs of mice and bioluminescence signal of tumors quantified over time; single tumors are shown. C, E, and G, Estimation of survival over time after TKI treatment based on bone and lung tumors. Absolute numbers are reported in the table. P value (one-way ANOVA with Tukey honestly significant difference post hoc test) with median OS and 95% CI of ratio after the log-rank (Mantel–Cox) test. Axi, axitinib; Cabo, cabozantinib; Lenv, lenvatinib; MBP, median bone progression; Rx, second-line treatment; WD, withdrawal.

8 October 2024
Verified
Other
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
TKIs’ effect on blood vessels and immune infiltrate in LVRCC67 model. A) Representative images of LVRCC67 bone tumors captured by confocal microscope; tumor cells (green, PAX8), of CD8+ cells (yellow), blood vessels (CD31, red); nuclei (blue, DAPI); dotted line, tumor edge; B) Quantification of blood vessel area, number of CD8+ cells over tumor area and CD8+ cell distribution, mean + SEM, n=3/group. P values by one-way ANOVA with Tukey’s HSD post hoc test; p < 0.01 = **. Bar, 100 µm. BV-blood vessels; V-vehicle, A-axitinib, C-cabozantinib, L-lenvatinib; Inner reg-inner region.

8 October 2024
Verified
Other
Open access
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
In vitro and in vivo effects of TKIs on blood vessels. A, Dose–response curve of axitinib, cabozantinib, and lenvatinib treatment of HUVECs, mean ± SD, n = 4. B, Schematic representation of the experimental approach. C and D, Impact of TKIs on vascularization of RENCA VHL− tumors in bone evaluated by IF analysis; representative images acquired by confocal microscopy (green, GFP; blue, DAPI; yellow, endomucin; red, laminin; C) and quantification are shown (D); dotted line, tumor area; mean ± SEM, n = 4–10/group; bar, 100 μm. E and F, Impact of TKIs on vascularization of RENCA VHL− tumors in lungs; representative images acquired by confocal microscopy (green, GFP; blue, DAPI; red, CD31; E) and quantifications are shown; dotted line, tumor area; mean ± SEM, n = 4–10/group; ar, 100 μm. P values by one-way ANOVA with Tukey honestly significant difference post hoc test; *, P < 0.05; **, P < 0.01; ***, P < 0.001. A, axitinib; BV, blood vessel; C, cabozantinib; Endo/Endom, endomucin; L, lenvatinib; Lam, laminin; RV−, RENCA VHL; V, vehicle.

8 October 2024
Verified
Other
Open access
PDF file
SMStefan Maksimovic
Stefan Maksimovic
NBNina C. Boscolo
Nina C. Boscolo
LPLudovica La Posta
Ludovica La Posta
SBSergio Barrios
Sergio Barrios
Mohammad Jad MoussaMohammad Jad Moussa
Mohammad Jad Moussa
EDEleonora Dondossola
Eleonora Dondossola
Blood vessel distance analysis in bone tumors. (1) Representative images of bone (VHL- RENCA) tumors captured by confocal microscope; tumor cells (green, GFP); blood vessels (yellow, endomucin; red, laminin), nuclei (blue, DAPI); (2) single endomucin channel and examples of measures (yellow bar lines) of blood vessel distance calculated in Fig. 3 D, F; dotted line, the area of tumor. Endo-endomucin; Lam-laminin.